CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.5255
19.6%
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0190
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Gritstone bio Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.2755
Open* 1.2955
1-Year Change* -55.44%
Day's Range* 1.2755 - 1.5255
52 wk Range 1.14-4.05
Average Volume (10 days) 1.38M
Average Volume (3 months) 49.05M
Market Cap 122.04M
P/E Ratio -100.00K
Shares Outstanding 95.34M
Revenue 10.23M
EPS -1.55
Dividend (Yield %) N/A
Beta 0.44
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 1, 2023 1.5255 0.2200 16.85% 1.3055 1.5355 1.2755
Nov 30, 2023 1.2755 -0.0400 -3.04% 1.3155 1.3655 1.2755
Nov 29, 2023 1.3055 0.0000 0.00% 1.3055 1.3455 1.2755
Nov 28, 2023 1.2955 -0.0300 -2.26% 1.3255 1.3655 1.2855
Nov 27, 2023 1.3555 0.0200 1.50% 1.3355 1.3555 1.2655
Nov 24, 2023 1.3555 0.0400 3.04% 1.3155 1.3855 1.2855
Nov 22, 2023 1.3055 0.0400 3.16% 1.2655 1.3255 1.2655
Nov 21, 2023 1.2655 -0.0600 -4.53% 1.3255 1.3255 1.2555
Nov 20, 2023 1.3155 -0.0400 -2.95% 1.3555 1.3855 1.3155
Nov 17, 2023 1.3555 0.0000 0.00% 1.3555 1.3955 1.2955
Nov 16, 2023 1.3555 -0.0500 -3.56% 1.4055 1.4655 1.3155
Nov 15, 2023 1.4355 0.0700 5.13% 1.3655 1.4955 1.3455
Nov 14, 2023 1.3555 -0.0600 -4.24% 1.4155 1.4755 1.3455
Nov 13, 2023 1.3755 -0.0500 -3.51% 1.4255 1.4555 1.3455
Nov 10, 2023 1.4155 -0.1400 -9.00% 1.5555 1.5655 1.4055
Nov 9, 2023 1.5555 -0.1300 -7.71% 1.6855 1.6855 1.5155
Nov 8, 2023 1.6755 -0.1200 -6.68% 1.7955 1.7955 1.6555
Nov 7, 2023 1.8155 0.0100 0.55% 1.8055 1.8455 1.7955
Nov 6, 2023 1.8255 -0.0500 -2.67% 1.8755 1.9055 1.7955
Nov 3, 2023 1.8755 0.0300 1.63% 1.8455 1.9555 1.8455

Gritstone bio, Inc. Events

Time (UTC) Country Event
Tuesday, December 5, 2023

Time (UTC)

16:00

Country

US

Event

Gritstone bio Inc at Goldman Sachs Catalyst Clinic (Virtual)
Gritstone bio Inc at Goldman Sachs Catalyst Clinic (Virtual)

Forecast

-

Previous

-
Thursday, March 7, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Gritstone bio Inc Earnings Release
Q4 2023 Gritstone bio Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 19.945 48.214 4.037 4.365 1.187
Total Operating Expense 140.373 123.423 110.054 102.305 66.771
Selling/General/Admin. Expenses, Total 28.97 25.933 21.411 19.409 11.806
Research & Development 111.403 97.49 88.643 82.896 54.965
Operating Income -120.428 -75.209 -106.017 -97.94 -65.584
Interest Income (Expense), Net Non-Operating 0.741 0.127 0.703 3.507 0.809
Net Income Before Taxes -119.687 -75.082 -105.314 -94.433 -64.775
Net Income After Taxes -119.687 -75.082 -105.314 -94.433 -64.775
Net Income Before Extra. Items -119.687 -75.082 -105.314 -94.433 -64.775
Net Income -119.687 -75.082 -105.314 -94.433 -64.775
Income Available to Common Excl. Extra. Items -119.687 -75.082 -105.314 -94.433 -64.775
Income Available to Common Incl. Extra. Items -119.687 -75.082 -105.314 -94.433 -64.775
Diluted Net Income -119.687 -75.082 -105.314 -94.433 -64.775
Diluted Weighted Average Shares 90.9183 78.8852 37.7924 33.5548 29.1938
Diluted EPS Excluding Extraordinary Items -1.31642 -0.95179 -2.78665 -2.81429 -2.21879
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -1.31642 -0.95179 -2.78665 -2.81429 -2.21879
Revenue 19.945 48.214 4.037 4.365 1.187
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 1.955 2.443 4.262 3.021 5.471
Revenue 1.955 2.443 4.262 3.021 5.471
Total Operating Expense 37.683 37.259 36.181 32.898 35.139
Selling/General/Admin. Expenses, Total 6.716 6.745 6.761 6.462 7.792
Research & Development 30.967 30.514 29.42 26.436 27.347
Operating Income -35.728 -34.816 -31.919 -29.877 -29.668
Interest Income (Expense), Net Non-Operating 0.494 0.834 0.629 -0.089 0.153
Net Income Before Taxes -35.256 -33.982 -31.29 -29.966 -29.515
Net Income After Taxes -35.256 -33.982 -31.29 -29.966 -29.515
Net Income Before Extra. Items -35.256 -33.982 -31.29 -29.966 -29.515
Net Income -35.256 -33.982 -31.29 -29.966 -29.515
Income Available to Common Excl. Extra. Items -35.256 -33.982 -31.29 -29.966 -29.515
Income Available to Common Incl. Extra. Items -35.256 -33.982 -31.29 -29.966 -29.515
Diluted Net Income -35.256 -33.982 -31.29 -29.966 -29.515
Diluted Weighted Average Shares 91.2242 87.8484 86.8949 86.5974 86.4486
Diluted EPS Excluding Extraordinary Items -0.38648 -0.38683 -0.36009 -0.34604 -0.34142
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.38648 -0.38683 -0.36009 -0.34604 -0.34142
Other, Net -0.022
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 182.878 220.59 175.39 131.273 157.636
Cash and Short Term Investments 171.887 201.633 171.058 127.776 153.11
Cash & Equivalents 38.191 81.312 36.801 46.382 52.183
Short Term Investments 116.389 108.346 1.002 70.368 100.927
Prepaid Expenses 6.35 4.982 3.114 2.725 4.077
Total Assets 240.754 278.106 221.567 184.389 189.558
Property/Plant/Equipment, Total - Net 38.816 44.542 43.449 50.338 29.494
Property/Plant/Equipment, Total - Gross 67.598 66.818 60.374 60.648 36.245
Accumulated Depreciation, Total -28.782 -22.276 -16.925 -10.31 -6.751
Other Long Term Assets, Total 15.029 8.357 2.728 2.778 2.428
Total Current Liabilities 34.801 39.956 26.988 19.5 15.108
Accounts Payable 8.694 4.23 9.578 4.621 4.825
Accrued Expenses 20.976 18.525 13.935 9.923 4.943
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 69.973 62.02 54.828 50.045 40.436
Total Long Term Debt 19.349 0 0 0 10.49
Capital Lease Obligations 0 10.49
Other Liabilities, Total 15.823 22.064 27.84 30.545 14.838
Total Equity 170.781 216.086 166.739 134.344 149.122
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.022 0.02 0.018 0.017 0.016
Additional Paid-In Capital 691.91 617.523 493.023 355.291 275.593
Retained Earnings (Accumulated Deficit) -521.071 -401.384 -326.302 -220.988 -126.402
Other Equity, Total -0.08 -0.073 0 0.024 -0.085
Total Liabilities & Shareholders’ Equity 240.754 278.106 221.567 184.389 189.558
Total Common Shares Outstanding 86.8949 67.9878 47.5527 36.333 28.8231
Other Current Assets, Total 3.977 12.59 1.218 0.29 0.449
Other Current Liabilities, Total 5.131 17.201 3.475 4.956 5.34
Cash 17.307 11.975 133.255 11.026
Total Receivables, Net 0.664 1.385 0.482
Accounts Receivable - Trade, Net 1.385
Long Term Investments 4.031 4.617
Long Term Debt 19.349
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 90.82 122.376 154.765 182.878 153.427
Cash and Short Term Investments 83.948 114.533 145.808 171.887 139.809
Cash & Equivalents 29.539 41.414 47.128 55.498 64.909
Short Term Investments 54.409 73.119 98.68 116.389 74.9
Total Receivables, Net 0.337 0.399 0.566 0.664 0.529
Prepaid Expenses 4.354 4.803 6.314 6.35 6.362
Other Current Assets, Total 2.181 2.641 2.077 3.977 6.727
Total Assets 187.217 222.623 209.952 240.754 205.242
Property/Plant/Equipment, Total - Net 89.861 92.428 35.98 38.816 40.993
Property/Plant/Equipment, Total - Gross 123.68 124.524 66.561 67.598 68.011
Accumulated Depreciation, Total -33.819 -32.096 -30.581 -28.782 -27.018
Other Long Term Assets, Total 6.536 7.819 19.207 15.029 10.822
Total Current Liabilities 23.383 22.111 24.672 34.801 32.313
Accounts Payable 4.265 4.925 5.975 8.694 2.885
Accrued Expenses 17.817 14.368 15.896 20.976 20.74
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.301 2.818 2.801 5.131 8.688
Total Liabilities 113.235 113.056 69.074 69.973 68.395
Total Long Term Debt 29.868 29.723 29.576 19.349 19.281
Other Liabilities, Total 59.984 61.222 14.826 15.823 16.801
Total Equity 73.982 109.567 140.878 170.781 136.847
Preferred Stock - Non Redeemable, Net 0 0 0 0
Common Stock 0.022 0.022 0.022 0.022 0.02
Additional Paid-In Capital 702.755 699.979 695.961 691.91 626.889
Retained Earnings (Accumulated Deficit) -628.743 -590.309 -555.053 -521.071 -489.781
Other Equity, Total -0.052 -0.125 -0.052 -0.08 -0.281
Total Liabilities & Shareholders’ Equity 187.217 222.623 209.952 240.754 205.242
Total Common Shares Outstanding 93.0754 91.2242 87.8484 86.8949 73.134
Long Term Investments 0 0 0 4.031 0
Accounts Receivable - Trade, Net 0
Long Term Debt 29.868 29.723 29.576 19.349 19.281
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -119.687 -75.082 -105.314 -94.433 -64.775
Cash From Operating Activities -115.946 -50.678 -89.102 -85.011 -38.162
Cash From Operating Activities 6.56 6.347 6.644 4.745 3.961
Non-Cash Items 21.708 19.421 14.499 10.332 2.443
Changes in Working Capital -24.527 -1.364 -4.931 -5.655 20.209
Cash From Investing Activities -12.964 -118.553 65.949 15.841 -59.103
Capital Expenditures -5.872 -5.463 -3.515 -16.173 -5.663
Other Investing Cash Flow Items, Total -7.092 -113.09 69.464 32.014 -53.44
Cash From Financing Activities 83.098 108.76 135.801 74.395 110.441
Issuance (Retirement) of Stock, Net 65.506 117.21 135.905 75.202 113.521
Net Change in Cash -45.812 -60.471 112.648 5.225 13.176
Financing Cash Flow Items -1.31 -8.394 -0.104 -0.807 -3.08
Issuance (Retirement) of Debt, Net 18.902 -0.056
Cash Interest Paid 0.647
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -33.982 -119.687 -88.397 -58.431 -28.916
Cash From Operating Activities -40.09 -115.946 -85.572 -59.788 -33.451
Cash From Operating Activities 1.799 6.56 4.769 3.093 1.589
Non-Cash Items 4.503 21.708 16.845 11.449 5.659
Changes in Working Capital -12.41 -24.527 -18.789 -15.899 -11.783
Cash From Investing Activities 21.173 -12.964 33.188 30.113 7.634
Capital Expenditures -1.567 -5.872 -4.389 -3.265 -1.812
Other Investing Cash Flow Items, Total 22.74 -7.092 37.577 33.378 9.446
Cash From Financing Activities 8.647 83.098 18.733 -0.607 -0.917
Financing Cash Flow Items -3.231 -1.31 -1.005 -0.959 -0.959
Issuance (Retirement) of Stock, Net 1.96 65.506 0.755 0.465 0.098
Net Change in Cash -10.27 -45.812 -33.651 -30.282 -26.734
Issuance (Retirement) of Debt, Net 9.918 18.902 18.983 -0.113 -0.056
Cash Interest Paid 0.436 0.647
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Point72 Asset Management, L.P. Hedge Fund 8.1371 7573680 -106187 2023-06-30 HIGH
Redmile Group, LLC Investment Advisor/Hedge Fund 7.3706 6860226 -66700 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 6.0574 5637975 3828281 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.3502 4049002 388103 2023-06-30 LOW
Versant Ventures Venture Capital 3.8261 3561150 0 2023-06-30 LOW
Avidity Partners Management LP Hedge Fund 2.9712 2765500 -94471 2023-06-30 HIGH
Frazier Healthcare Partners Venture Capital 2.5804 2401714 -2760634 2023-06-30 LOW
Balyasny Asset Management LP Hedge Fund 2.0221 1882048 -490982 2023-06-30 HIGH
Morgan Stanley & Co. LLC Research Firm 1.878 1747998 -55290 2023-06-30 MED
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.8008 1676058 931478 2023-06-30 LOW
Allen (Andrew R) Individual Investor 1.6368 1523429 -678717 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.6249 1512337 1239007 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.3918 1295437 584219 2023-06-30 HIGH
Assenagon Asset Management S.A. Investment Advisor 1.3411 1248264 -290104 2023-06-30 HIGH
Ensign Peak Advisors, Inc. Foundation 0.8572 797880 677353 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 0.8491 790316 -8197 2023-06-30 LOW
Palo Alto Investors LP Hedge Fund 0.7157 666127 0 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6814 634181 491876 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 0.4731 440348 -117417 2023-06-30 LOW
Hawryluk (Matthew Ph.D.) Individual Investor 0.4042 376207 191771 2023-02-02 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Gritstone bio, Inc. Company profile

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.
Industry: Biopharmaceuticals

5959 Horton Street, Suite 300
EMERYVILLE
CALIFORNIA 94608
US

Income Statement

  • Annual
  • Quarterly

News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

People also watch

US100

16,001.20 Price
+0.470% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Gold

2,072.25 Price
+1.760% 1D Chg, %
Long position overnight fee -0.0193%
Short position overnight fee 0.0111%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
-0.100% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

74.50 Price
-1.560% 1D Chg, %
Long position overnight fee -0.0136%
Short position overnight fee -0.0083%
Overnight fee time 22:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading